Home Healthcare IT China Active Implantable Medical Devices Market Size, Top Share, Forecast to 2032
Select Regional / Country Report

China Active Implantable Medical Devices Market Size, Share & Trends Analysis Report By Product (Implantable Cardioverter Defibrillators, Implantable Cardiac Pacemakers, Ventricular Assist Devices, Implantable Heart Monitors/Insertable Loop Recorders, Neurostimulators, Implantable Hearing Devices), By End-User (Hospitals, Ambulatory Surgery Center, Specialty Clinics) and Forecasts, 2024-2032

Report Code: SRHI56668DR
Last Updated : Nov 27, 2024
Author : Debashree Bora
Starting From
USD 1850
Buy Now

China Active Implantable Medical Devices Market Size

The China active implantable medical devices market size was valued at USD 1.82 billion in 2023 and is projected to reach from USD 2.00 billion in 2024 to USD 4.32 billion by 2032, growing at a CAGR of 10.1% during the forecast period (2024–2032). This surge is attributed to rapid healthcare advancements, a rising prevalence of chronic diseases, and increasing investment in medical technology infrastructure. Furthermore, the demand for implantable cardioverter defibrillators (ICDs), neurostimulators, and pacemakers is expected to grow exponentially, driven by urbanization, lifestyle changes, and technological innovation.

China Active Implantable Medical Devices Market

China Active Implantable Medical Devices Market Growth Factors

High prevalence of cardiovascular diseases and government initiatives

Cardiovascular diseases (CVDs) are the leading cause of mortality in China, accounting for approximately 40% of total deaths as per the China Cardiovascular Health Alliance (CCHA). Lifestyle changes, including unhealthy diets and sedentary behavior, have led to a surge in hypertension and heart-related disorders, boosting demand for AIMDs like ICDs and pacemakers.

Furthermore, government-led healthcare reforms, such as the Healthy China 2030 initiative, aim to enhance the accessibility and affordability of advanced medical devices. Public and private investments in hospital infrastructure and medical technology further drive adoption. Companies like MicroPort Scientific Corporation are capitalizing on these opportunities, expanding their AIMD portfolios with localized solutions to meet China’s unique healthcare needs.

Market Restraining Factors

High costs and regulatory hurdles

Despite growing demand, the high cost of AIMDs poses a significant barrier to widespread adoption in China. For instance, the average price of an ICD ranges from CNY 80,000 to 120,000 (USD 11,000–16,000), making it inaccessible for many patients without adequate insurance coverage. While government subsidies and reimbursement policies are improving, gaps remain, particularly in rural areas.

Moreover, China’s stringent regulatory framework for medical devices, governed by the National Medical Products Administration (NMPA), can delay market entry for new products. Local manufacturers face intense competition from global players, and the lengthy approval process hinders innovation. Addressing these challenges is essential to ensure the sustained growth of the AIMDs market in China.

Market Opportunity

Ai and iot integration in aimds

The integration of artificial intelligence (AI) and the Internet of Things (IoT) into AIMDs represents a transformative opportunity for the Chinese market. AI-enabled AIMDs offer advanced features like predictive diagnostics and real-time monitoring, improving patient outcomes and reducing healthcare costs.

According to the China Academy of Information and Communications Technology (CAICT), the country’s AI healthcare market is expected to exceed USD 25 billion by 2025, highlighting the growing appetite for digital health solutions. IoT-connected neurostimulators and pacemakers are also gaining traction, driven by the increasing adoption of telemedicine and remote patient monitoring systems.

Moreover, collaborations between technology giants like Tencent and medical device manufacturers are accelerating the development of smart AIMDs tailored for the Chinese population. These innovations align with China’s vision of digital healthcare transformation, presenting significant growth opportunities.

Study Period 2020-2032 CAGR 10.1%
Historical Period 2020-2022 Forecast Period 2024-2032
Base Year 2023 Base Year Market Size USD 1.82 billion
Forecast Year 2032 Forecast Year Market Size USD 4.32 billion
Talk to us
If you have a specific query, feel free to ask our experts.

Citywise Insights

The market is characterized by regional disparities in healthcare infrastructure, urbanization trends, and targeted investments in medical technology. Key cities drive growth through innovation and accessibility.

  • Beijing is a leader in healthcare innovation and AIMD adoption. Institutions like Peking Union Medical College Hospital (PUMCH) pioneer advanced treatments, attracting patients nationwide. The city’s focus on AI in healthcare fosters partnerships between medtech companies and research institutions.
  • Shanghai’s robust healthcare infrastructure and high prevalence of chronic diseases make it a significant market for AIMDs. Companies like MicroPort Scientific Corporation, headquartered in the city, drive innovation in ICDs and neurostimulators. Shanghai’s advanced hospital networks and medical research facilities support market growth.
  • Guangzhou, known for its rapidly expanding healthcare services, emphasizes affordable and accessible treatments. The city’s large aging population and rising cardiac disease burden fuel the demand for pacemakers and ICDs. Partnerships with global manufacturers enhance the availability of advanced devices.
  • Shenzhen, as a technology hub, integrates AI and IoT into healthcare, advancing the AIMDs market. Startups and tech giants like Huawei collaborate with medical device manufacturers to develop smart solutions. Shenzhen’s innovation ecosystem accelerates market penetration.
  • Chengdu’s growing healthcare infrastructure and focus on improving rural healthcare access make it a promising market. Regional hospitals are adopting AIMDs for cardiovascular and neurological treatments, supported by government subsidies and training programs.
Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports


China Active Implantable Medical Devices Market Segmentation Analysis

By product

Implantable Cardioverter Defibrillators dominate the product segment and are expected to grow at a CAGR of 10.9% over the forecast period, driven by rising incidences of cardiac arrhythmias and sudden cardiac arrest. Innovations in leadless ICDs, MRI-compatible devices, and government subsidies fuel their adoption. Domestic players like Lepu Medical are expanding their portfolios to ensure affordable, high-quality solutions.

By end user

Hospitals dominate the end-user segment and are expected to grow at a CAGR of 9.9% during the forecast period. China’s significant investment in public and private hospitals under the Healthy China 2030 initiative ensures the availability of advanced medical technologies. High patient footfall in tertiary care hospitals further solidifies their position as the primary end-users.

Market Size By Product

Market Size By Product
  • Implantable Cardioverter Defibrillators
  • Implantable Cardiac Pacemakers
  • Ventricular Assist Devices
  • Implantable Heart Monitors/Insertable Loop Recorders
  • Neurostimulators
  • Implantable Hearing Devices


  • List of key players in China Active Implantable Medical Devices Market

    1. Medtronic PLC
    2. Abbott Laboratories
    3. Boston Scientific Corporation
    4. Livanova PLC
    5. Nurotron Biotechnology Co. Ltd.
    6. Biotronik Se & Co., Kg
    7. William Demant Holding A/S
    8. Cochlear Limited
    9. Sonova Holding AG
    China Active Implantable Medical Devices Market Share of Key Players

    Analyst’s Perspective

    As per our analyst, China's active implantable medical devices market is poised for rapid expansion in the coming years. This growth is primarily driven by China’s robust healthcare reforms, increasing chronic disease burden, and advancements in medical technology. The integration of AI and IoT in AIMDs aligns with the country’s digital health initiatives, creating a favorable environment for innovation.

    Moreover, China’s focus on improving rural healthcare access and strategic partnerships between domestic and global manufacturers ensures equitable growth. Rising awareness, government incentives, and a strong emphasis on R&D position the AIMDs market as a critical component of China’s healthcare transformation.


    China Active Implantable Medical Devices Market Segmentations

    By Product (2020-2032)

    • Implantable Cardioverter Defibrillators
      • Transvenous Implantable Cardioverter Defibrillators
        • Biventricular Implantable Cardioverter Defibrillators/Cardiac
        • Resynchronization Therapy Defibrillators
        • Dual-Chamber Implantable Cardioverter Defibrillators
        • Single-Chamber Implantable Cardioverter Defibrillators
      • Subcutaneous Implantable Cardioverter Defibrillators
    • Implantable Cardiac Pacemakers
    • Ventricular Assist Devices
    • Implantable Heart Monitors/Insertable Loop Recorders
    • Neurostimulators
      • Spinal Cord Stimulators
      • Deep Brain Stimulators
      • Sacral Nerve Stimulators
      • Vagus Nerve Stimulators
      • Gastric Electrical Stimulators
    • Implantable Hearing Devices
      • Active Hearing Implants
      • Non-active/Passive Hearing Implants

    By End-User (2020-2032)

    • Hospitals
    • Ambulatory Surgery Center
    • Specialty Clinics

    Frequently Asked Questions (FAQs)

    How much is the China active implantable medical devices market worth?
    Straits research predicts that the China active implantable medical devices market size was valued at USD 1.82 billion in 2023 and is projected to reach from USD 2.00 billion in 2024 to USD 4.32 billion by 2032.
    The China market growth rate growing at a 10.1% from 2024 to 2032.
    The high prevalence of cardiovascular diseases and government initiatives, is a key growth factor driving advancements in active implantable medical devices.
    Beijing holds the largest market share with its healthcare innovation and AIMD adoption.
    Currently, the hospital segment dominates the market, fueled by significant investment in public and private hospitals.


    We are featured on :